Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Terevalefim - Elicio Therapeutics

Next Previous
X
Search
Drug Profile

Terevalefim - Elicio Therapeutics

Alternative Names: ANG-3777; BB 3; Hepatocyte growth factor mimetic - Elicio Therapeutics; Refanalin; SNV-003

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angion Biomedica
  • Developer Elicio Therapeutics
  • Class Anti-ischaemics; Antifibrotics; Heart failure therapies; Pyrazoles; Small molecules; Thiophenes; Urologics; Vascular disorder therapies
  • Mechanism of Action Proto-oncogene protein c-met stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Delayed graft function
  • Phase II Acute kidney injury; Acute lung injury; Renal failure
  • Preclinical Brain injuries
  • No development reported Heart failure
  • Discontinued Hepatic fibrosis; Myocardial infarction; Stroke

Most Recent Events

  • 01 Jun 2023 Angion Biomedica has merged with Elicio Therapeutics to form Elicio Therapeutics
  • 02 Aug 2022 Vifor Pharma has been acquired by CSL and renamed to CSL Vifor
  • 14 Dec 2021 Efficacy and adverse events data of a phase II GUARD trial in Acute kidney injury released by the company

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top